1
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
1
Rare Diseases
across 4 areas
0
News (30d)
Quiet
LAVA Therapeutics is a company with 1 orphan drug designation across 1 rare disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell chronic lymphocytic leukemia | immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio